Aclaris opens mid-stage lichen planus study for oral ITK/JAK3 drug modzatinib
The 100-patient placebo-controlled trial will read out its first cohort, in oral erosive disease, in the second half of 2027, leaving the commercial case unproven for now.
16 Nov 2026 · Aclaris Therapeutics, Inc. ACRS · Company news
Aclaris Therapeutics has dosed off a new stage in the development of modzatinib, also known as ATI-2138, by launching a Phase 2b study in patients with moderate-to-severe lichen planus. The company announced the move on 16 November 2026.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Aclaris Therapeutics, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
More Pipeline & R&DAll →
Pipeline & R&D
Summit starts Phase III HARMONi-10 of ivonescimab against durvalumab in Stage III NSCLC
18 Nov 2026 · Summit Therapeutics Inc. SMMT · Company news
Pipeline & R&D
NeOnc deck reports Phase 2a intranasal NEO100 results in recurrent IDH1-mutant glioma
18 Nov 2026 · Neonc Technologies Holdings, Inc. NTHI · Company news
Pipeline & R&D
Optimi Health seeks to make psilocybin depression study randomised Phase 2b; MDMA Phase 3 planned
18 Nov 2026 · Optimi Health Corp. OPTH · Company news
Pipeline & R&D
Can-Fite completes dosing in interim cohort of Phase III piclidenoson psoriasis trial
18 Nov 2026 · Can-Fite BioPharma Ltd. CANF · Company news
Pipeline & R&D
Inhibrx reports 62.7% response rate for ozekibart combination in relapsed Ewing sarcoma
17 Nov 2026 · Inhibrx Biosciences, Inc. INBX · Company news
Pipeline & R&D
Adagene and City of Hope launch Phase 1 trial of ivonescimab plus muzastotug in colorectal cancer
17 Nov 2026 · Adagene Inc. ADAG · Company news